Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMalignant neoplasms of respiratory and intrathoracic organsICD-10-CM c32-malignant-neoplasm-of-larynx
    Ask Trek AI about this page

    ICD-10-CM Code For Malignant Neoplasm Of Larynx: Group Overview

    The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code group C32 includes malignant neoplasms of the larynx, capturing tumors by anatomic subsite and extent of disease such as localized, regional, or metastatic involvement. These ICD-10-CM diagnosis codes are used to document clinical encounters for primary laryngeal cancer, recurrent disease, and metastatic spread, capturing tumor location and severity. Accurate coding within the ICD-10-CM C32 group supports proper claim adjudication, complete clinical documentation, and appropriate reimbursement.

    Customize your policy alerts

    Sign up for ICD-10-CM Code For Malignant Neoplasm Of Larynx: Group Overview policy alerts

    Get alerted when relevant policies change without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    ICD-10-CM C32: Malignant Neoplasm Of Larynx Overview

    The diagnoses in this group represent malignant tumors originating in the larynx, including subsite-specific cancers and advanced disease with regional or distant spread. They target the respiratory and intrathoracic organ system with direct impact on airway, voice, and swallowing function. Accurate coding matters for appropriate clinical documentation and reimbursement, and it supports correct disease staging and treatment planning.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    When to Use

    Use a code from this group when a clinical encounter documents a diagnosed malignant neoplasm of the larynx with specification of subsite and disease extent. Apply the most specific code available to reflect localization, laterality when applicable, and whether the condition is primary, recurrent, or metastatic.

    ICD-10-CM Codes

    6 rows

    ICD-10-CM CodeDescription
    C32.0Malignant neoplasm of glottis
    C32.1Malignant neoplasm of supraglottis
    C32.2Malignant neoplasm of subglottis
    C32.3Malignant neoplasm of laryngeal cartilage
    C32.8Malignant neoplasm of overlapping sites of larynx
    C32.9Malignant neoplasm of larynx, unspecified

    DRG Codes

    6 rows

    DRG CodeDescription
    011Tracheostomy for Face, Mouth and Neck Diagnoses or Laryngectomy with MCC
    012Tracheostomy for Face, Mouth and Neck Diagnoses or Laryngectomy with CC
    013Tracheostomy for Face, Mouth and Neck Diagnoses or Laryngectomy without CC/MCC
    146Ear, Nose, Mouth and Throat Malignancy with MCC
    147Ear, Nose, Mouth and Throat Malignancy with CC
    148Ear, Nose, Mouth and Throat Malignancy without CC/MCC

    Typical Clinical Scenarios

    • An older patient with a long smoking history presents to the otolaryngology clinic with progressive hoarseness, dysphonia, and a palpable neck lymph node. Flexible laryngoscopy reveals an exophytic lesion involving the glottic vocal cords with impaired vocal fold mobility; biopsy confirms squamous cell carcinoma confined to the glottis. A code from this group is assigned to capture the primary malignant neoplasm of the glottis. Typical codes: C32.0
    • A middle-aged patient reports persistent throat pain, odynophagia, and referred otalgia; imaging and endoscopic evaluation identify a tumor centered on the supraglottic larynx with extension to the epiglottis and regional cervical lymphadenopathy. The patient is referred urgently for staging and multidisciplinary treatment planning because the lesion involves supraglottic structures and has potential airway compromise. A supraglottic primary malignant laryngeal neoplasm code is used to document the anatomic site and direct care decisions. Typical codes: C32.1
    • A patient with a previously treated laryngeal cancer presents years later with new dysphagia and a mass at the subglottic region on exam; biopsy shows a new primary or recurrent malignancy located in the subglottic larynx, and the encounter also notes local invasion into adjacent intrathoracic structures. Coding captures a malignant neoplasm of the subglottic larynx or overlapping lesion when site is not limited to a single subsite. Typical codes: C32.2, C32.8

    Related Codes

    C30-MALIGNANT-NEOPLASM-NASAL-CAVITY-MIDDLE-EAR

    ICD-10-CM Code For Malignant Neoplasm Of Nasal Cavity And Middle Ear: Group Overview

    C31-MALIGNANT-NEOPLASM-ACCESSORY-SINUSES

    ICD-10-CM Code For Malignant Neoplasm Of Accessory Sinuses: Group Overview

    C33-MALIGNANT-NEOPLASM-OF-TRACHEA

    ICD-10-CM Code For Malignant Neoplasm Of Trachea: Group Overview

    C34-MALIGNANT-NEOPLASM-OF-BRONCHUS-AND-LUNG

    ICD-10-CM Code For Malignant Neoplasm Of Bronchus And Lung: Group Overview

    C37-MALIGNANT-NEOPLASM-OF-THYMUS

    ICD-10-CM Code For Malignant Neoplasm Of Thymus: Group Overview

    C38-MALIGNANT-NEOPLASM-HEART-MEDIASTINUM-PLEURA

    ICD-10-CM Code For Malignant Neoplasm Of Heart Mediastinum And Pleura: Group Overview

    C39-MALIGNANT-NEOPLASM-OTHER-ILL-DEFINED-SITES

    ICD-10-CM Code For Malignant Neoplasm Of Other And Ill-Defined Sites In The Respiratory System And Intrathoracic Organs: Group Overview

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.